Email
Password
Remember meForgot password?
    Log in with Twitter

article imageProgress with topical treatment of retinal disease

By Tim Sandle     Dec 5, 2014 in Health
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company, has announced it has secured a patent on a novel compound called SF0166. This is a small molecule integrin antagonist designed to treat retinal disease.
The types of conditions that the new molecule can potentially treat includes age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), via topical administration to the eye.
With these conditions, AMD is a medical condition that usually affects older adults and results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in "dry" and "wet" forms. DME occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell (edema). The swelling may distort a person's central vision.
Topical administration of medications (eye drops) for treating the retina in order to eliminate the need to inject compounds to the back of the eye has been seen as the gold standard for medics. However, preparing such a treatment has presented a great challenge. As it stands, most current treatments involve injections into the eye.
The discovery of the new molecule by SciFluor Life Sciences means that a drug that could localize in the back of the eye after administration as an eye drop can go into trial. If successful, this would remove the need for repeated injections.
SF0166 is a powerful and selective small molecule inhibitor of integrin αvβ3 can it can be distributed to the retina in high concentrations. Pre-clinical assays have shown it to be effective in initial studies.
More about Retina, Eyes, Disease
More news from
Latest News
Top News